Kidney Diseases is an esteemed open-access journal published by KARGER that has been at the forefront of nephrology research since its inception in 2015. With an impressive Scopus ranking of #13 out of 81 in the field of Medicine Nephrology, placing it in the top 84th percentile, the journal has established itself as a vital resource for researchers, clinicians, and students interested in advancing knowledge on kidney health, disorders, and innovative treatment strategies. This journal aims to disseminate cutting-edge findings and clinical insights over a converged publication span from 2019 to 2024, fostering global collaboration and dialogue within the scientific community. With its commitment to open access, Kidney Diseases ensures that critical research is freely accessible, promoting wider dissemination of knowledge and the development of effective therapeutic interventions.

Journal of Renal Injury Prevention, published by NIKAN RESEARCH INST, is an essential resource in the fields of nephrology and urology, catering to the growing need for specialized knowledge in the prevention and management of renal injuries. Since its establishment in 2017, this journal has worked diligently to contribute to the global discourse on renal health, exploring innovative strategies and emerging therapies. With an ISSN of 2345-2781 and an E-ISSN of 2345-2781, it aims to provide high-quality research that addresses critical aspects of kidney injuries and their prevention. While currently classified in the Q4 quartile for both nephrology and urology, the journal aspires to enhance its impact by nurturing robust discussions among researchers and clinicians alike. The journal is based in Isfahan, Iran, and welcomes submissions that advance our understanding of renal pathology. Given its commitment to the advancement of medical science, the Journal of Renal Injury Prevention is poised to play a key role in shaping future research and clinical practices in the field.

Case Reports in Nephrology and Dialysis, published by KARGER, is a vital peer-reviewed journal dedicated to the dissemination of case reports and innovative findings in the fields of nephrology and dialysis. Since its inception in 2015, this Open Access journal has aimed to foster knowledge exchange and improve patient outcomes through comprehensive case studies, clinical insights, and recent advancements in renal healthcare. Based in Switzerland, the journal is poised to serve a global audience, accommodating research that spans diverse geographical and clinical contexts. Currently ranked in the Q3 category for nephrology in 2023, it underscores its burgeoning influence in the medical literature, despite its relatively nascent presence. As a valuable resource for researchers, healthcare professionals, and students, it provides a platform for sharing unique cases that enrich the understanding of complex renal issues and challenges faced in dialysis. With an emphasis on high-quality, accessible research, Case Reports in Nephrology and Dialysis is committed to advancing nephrology and dialysis practices through collaboration and knowledge sharing.

European Urology Oncology is a premier academic journal dedicated to advancing the field of urological oncology through innovative research and interdisciplinary collaboration. Published by Elsevier and based in the Netherlands, this journal runs on the principles of providing high-quality, peer-reviewed content that meets the evolving needs of professionals in medicine, surgery, and oncology. With an impressive 2023 categorization in the Q1 quartiles across multiple disciplines including Medicine (Miscellaneous), Oncology, and Urology, the journal demonstrates its pivotal role in disseminating essential findings that enhance clinical practices. The E-ISSN of this journal is 2588-9311, ensuring accessibility to groundbreaking articles that influence treatment methodologies and patient outcomes. Researchers and professionals relying on the latest evidence in urology and oncology will find this journal essential for keeping abreast of cutting-edge developments and clinical insights that shape the future of healthcare.

Leukemia Research Reports, published by Elsevier Advanced Technology, is a prominent open-access journal dedicated to the latest advancements in the field of hematology and oncology. Since its launch in 2012, this journal has been a vital resource for researchers, healthcare professionals, and students aiming to disseminate and access high-quality research articles focused on various aspects of leukemia and related blood disorders. With an impact factor indicative of its significance in the field, Leukemia Research Reports currently holds a Q3 quartile ranking in both Hematology and Oncology, and is included in key databases such as Scopus. The journal not only embraces a commitment to open access, ensuring that research is freely available, but also actively promotes collaborations that strive to enhance our understanding and treatment of leukemia. Based in the United Kingdom, this journal continues to play a crucial role in fostering innovation and knowledge sharing within the medical community.

Chinese Clinical Oncology is a distinguished journal dedicated to advancing the field of oncology and clinical research, published by AME Publishing Company. Since its inception in 2012, this journal has established its significance within the academic community, boasting an impactful presence as evidenced by its 2023 Scopus rankings, where it is positioned in the 47th percentile in the field of oncology. This open access journal features a diverse range of research, reviews, and clinical studies that aim to bridge the gap between experimental and clinical oncology, making it an invaluable resource for researchers, medical professionals, and students alike. The journal is based in Hong Kong and is committed to publishing studies that contribute to the understanding and treatment of cancer, with a strong focus on innovative methodologies and emerging therapies. With a current categorization of Q2 in Medicine and Q3 in Oncology, Chinese Clinical Oncology offers a robust platform for scholarly communication and is pivotal for those involved in cancer research and treatment.

Canadian Journal of Urology, published by CANADIAN J UROLOGY, is a prominent peer-reviewed journal dedicated to advancing the field of urology and its allied disciplines. Established in 2000, this journal has consistently aimed to provide a platform for comprehensive research, clinical studies, and innovative practices in urology and general medicine, ensuring that professionals remain at the forefront of medical advancements. With a reputation reflected in its 2023 Scopus ranking of Q3 in both Urology and Medicine (miscellaneous), the journal serves as an essential resource for researchers and practitioners seeking to enhance their knowledge and application of urological sciences. Although it is not an Open Access journal, its impactful findings contribute significantly to the medical community in Canada and beyond, promoting evidence-based practices and contributing to better patient outcomes. As the journal converges into 2024, it continues to welcome high-quality submissions that explore critical challenges and advancements in urology.

Hematology Reports is an esteemed academic journal in the field of hematology, dedicated to advancing the understanding of blood disorders and their treatment. Published by MDPI, a leading Swiss publisher known for its commitment to open access since 2009, this journal provides a valuable platform for researchers and healthcare professionals to disseminate innovative findings and foster collaboration within the academic community. The journal features an array of articles ranging from clinical studies to laboratory research, and is indexed in Scopus, where it currently holds a rank of 113 out of 137 in the Medicine - Hematology category, placing it in the 17th percentile. As an open-access journal, Hematology Reports ensures that critical research is accessible to a global audience, supporting the dissemination of knowledge that has the potential to improve patient outcomes. This journal is an essential resource for those engaged in the study and treatment of hematological conditions, encouraging dialogue and the exchange of ideas to enhance clinical practices.

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, published by Elsevier Science Inc, stands at the forefront of the medical literature dedicated to advancing our understanding of cancer and blood disorders. With its ISSN 1040-8428 and E-ISSN 1879-0461, this prestigious journal boasts an impressive impact factor, reflecting its significance in the fields of Geriatrics, Hematology, and Oncology. Notably, it has achieved the distinction of being ranked in the top quartile (Q1) for these categories as of 2023, with Scopus rankings placing it in the 93rd percentile in Geriatrics and Gerontology, 87th in Oncology, and 85th in Hematology. Since its inception in 1983 and continuing until 2024, the journal serves as a critical resource for researchers, medical professionals, and students alike, aiming to publish high-quality, peer-reviewed articles that facilitate knowledge exchange and promote innovation in clinical practices and therapeutic strategies. While the journal is not open access, it remains widely accessible through various academic institutions, ensuring that vital research findings reach those who need them most.

Molecular and Clinical Oncology is a dynamic journal published by SPANDIDOS PUBL LTD, aimed at advancing the understanding of cancer biology and treatment modalities. With an ISSN of 2049-9450 and an E-ISSN of 2049-9469, the journal serves as a critical platform for researchers and clinicians dedicated to uncovering novel insights in molecular oncology and enhancing clinical practices. As a testament to its growing influence, the journal has achieved a Q3 ranking in Oncology and a Q4 ranking in Cancer Research for the year 2023, reflecting its commitment to publishing high-quality research. Although currently not an Open Access publication, the journal offers crucial subscription options, ensuring comprehensive access to groundbreaking studies and innovations in the field. With converged years spanning 2018 to 2024, the journal is set to continue enriching the academic community with its valuable contributions, ultimately empowering researchers, professionals, and students engaged in the fight against cancer.